Tekmira Pharmaceuticals (TSX:TKM, NASDAQ:TKMR) combines genetics research with the fields of medicine and therapeutics to develop products used in the management of illnesses. The Company’s key strengths include its leading technology capabilities and a strong intellectual property portfolio including the delivery of siRNA (small interfering RNA) delivery using lipid nanoparticle (LNP) technology in the treatment of disease. Tekmira has collaborative or partnership agreements with leading companies in the RNAi field, including Alnylam Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Halo-Bio RNAi Therapeutics, Inc., Merck & Co. Inc., Pfizer Inc., Takeda Pharmaceutical Company, and the United States Government’s Transformational Medical Technologies (TMT) Program.
Click here to read more about Tekmira Pharmaceuticals (TSX:TKM, NASDAQ:TKMR) on Life Science Investing News
